Crizotinib

• Crizotinib is a targeted therapy used for specific types of non-small cell lung cancer (NSCLC).
• It works by inhibiting the activity of ALK, ROS1, and sometimes MET kinases, which drive cancer growth.
• Patients are selected for Crizotinib treatment based on diagnostic testing for these genetic alterations.
• Common side effects include visual disturbances, nausea, and diarrhea, with close monitoring required for more serious issues like liver toxicity.
• This medication represents a personalized approach to cancer treatment, improving outcomes for eligible patients.

What is Crizotinib?

Crizotinib is an oral, small-molecule tyrosine kinase inhibitor (TKI) that has revolutionized the treatment landscape for certain types of lung cancer. It is specifically approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are characterized by anaplastic lymphoma kinase (ALK) or ROS1 gene rearrangements. These genetic alterations are critical drivers of cancer cell proliferation and survival in a subset of NSCLC patients, making Crizotinib a cornerstone of precision medicine in this context.

The development of Crizotinib marked a pivotal shift towards therapies that target specific molecular abnormalities within cancer cells, rather than relying solely on broad-spectrum chemotherapy. Its efficacy is directly linked to the presence of these genetic markers, which are identified through molecular diagnostic testing prior to treatment initiation. This targeted approach allows for more effective treatment with potentially fewer side effects compared to traditional chemotherapy for eligible patients.

Crizotinib Mechanism of Action and Therapeutic Uses

The Crizotinib mechanism of action involves selectively inhibiting the activity of several receptor tyrosine kinases, primarily ALK, ROS1, and to a lesser extent, MET. In cancer cells with ALK or ROS1 gene rearrangements, these kinases become constitutively active, sending continuous signals that promote uncontrolled cell growth and division. By binding to and blocking the ATP-binding site of these kinases, Crizotinib effectively shuts down these aberrant signaling pathways, leading to inhibition of tumor cell proliferation and induction of apoptosis (programmed cell death).

The primary Crizotinib therapeutic uses are in the treatment of advanced NSCLC. It is indicated for patients with ALK-positive metastatic NSCLC and ROS1-positive metastatic NSCLC. Clinical studies have shown significant improvements in progression-free survival and overall response rates for patients treated with Crizotinib compared to standard chemotherapy. For instance, ALK rearrangements are found in approximately 3-7% of NSCLC cases, while ROS1 rearrangements occur in about 1-2% of NSCLC patients, as reported in various medical literature. Its use underscores the importance of molecular profiling in guiding treatment decisions in modern oncology.

Crizotinib Side Effects and Important Drug Information

Like all medications, Crizotinib can cause side effects, ranging from mild to severe. Understanding Crizotinib side effects is crucial for patients and healthcare providers to manage treatment effectively. Common side effects often include:

• Visual disturbances (e.g., blurred vision, double vision, flashes of light)
• Nausea and vomiting
• Diarrhea or constipation
• Edema (swelling), particularly in the hands, feet, and face
• Fatigue
• Decreased appetite
• Dizziness

More serious, though less common, side effects can include liver toxicity (hepatotoxicity), interstitial lung disease (ILD), bradycardia (slow heart rate), and severe vision loss. Regular monitoring of liver function tests, vision, and heart rate is therefore an essential part of Crizotinib drug information and patient management. Patients are typically advised to report any new or worsening symptoms promptly to their healthcare provider. Crizotinib is taken orally, usually twice daily, and the dosage may be adjusted based on individual tolerability and response. It is vital for patients to adhere strictly to their prescribed regimen and attend all scheduled follow-up appointments for monitoring.